Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mod Pathol ; 10(2): 142-8, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9127320

ABSTRACT

c-erbB-3 is a new member of the Type I growth factor receptor family that includes epidermal growth-factor receptor (also called c-erbB-1) and HER-2/neu (also called c-erbB-2). Frequency and significance of c-erbB-3 overexpression in lung cancers have not been reported previously. A series of 549 cases of primary lung carcinomas were immunostained with a monoclonal anti-human c-erbB-3 antibody (Clone RTJ.1) using formalin-fixed, paraffin-embedded archival tissue. Sharp membranous staining or punctate cytoplasmic staining was interpreted as positive and scored 0 (< 5% of tumor cells), 1 (5-9%), 2 (10-49%), or 3 (> or = 50%). Medical records were reviewed for clinical data, including stage and survival. Actuarial cumulative survival analysis with the Mantel-Cox test was performed on 443 cases that had a single primary site in the lung of pure non-small cell carcinoma (adenocarcinoma, squamous cell carcinoma, large cell carcinoma) and that also had follow-up data for more than 3 months. In all stages, squamous cell carcinoma showed the greatest rate of high c-erbB-3 positivity (score, 3) (34/119; 28.6%), followed by adenocarcinoma (41/256; 15.9%) and large cell carcinoma (7/66; 10.6%). Patients with high c-erbB-3 expression (score, 3) survived for significantly shorter times than did patients with low c-erbB-3-expression (score, 0-2) in Stages III and IV (P = 0.002), but not in Stage I or II non-small cell lung carcinomas. In conclusion, high c-erbB-3 expression in advanced non-small cell lung carcinomas might be an adverse prognostic factor. This finding suggests that c-erbB-3 might be a potential target for molecular therapy in advanced non-small cell lung carcinomas.


Subject(s)
Biomarkers, Tumor/biosynthesis , Carcinoma, Non-Small-Cell Lung/metabolism , ErbB Receptors/biosynthesis , Lung Neoplasms/metabolism , Proto-Oncogene Proteins/biosynthesis , Adenocarcinoma/metabolism , Adenocarcinoma/mortality , Adult , Aged , Aged, 80 and over , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/mortality , ErbB Receptors/analysis , Female , Humans , Lung Neoplasms/mortality , Male , Middle Aged , Prognosis , Proto-Oncogene Proteins/analysis , Receptor, ErbB-3 , Survival Analysis
2.
Am J Pathol ; 145(1): 80-5, 1994 Jul.
Article in English | MEDLINE | ID: mdl-7913296

ABSTRACT

Keratinocyte growth factor (KGF) causes a proliferation of pancreatic ductal epithelial cells in adult rats after daily systemic administration for 1 to 2 weeks. Even before the proliferation of intralobular ducts is histologically evident, KGF also induces proliferating cell nuclear antigen expression within the ductal epithelium of intercalated, intralobular, and interlobular ducts. KGF also causes incorporation of 5-bromodeoxyuridine in ductal epithelial cells. Epithelial cell proliferation is histologically most prominent at the level of the intralobular ducts adjacent to and within the islets of Langerhans. Pancreatic ductal proliferation is not histologically apparent in rats sacrificed 7 to 10 days after the cessation of KGF administration. The pancreatic hormones insulin, glucagon, somatostatin, and pancreatic polypeptide are normally distributed within islets that demonstrate intrainsular ductal proliferation. The proliferating ductal epithelium does not show endocrine differentiation as evidenced by the lack of immunoreactivity for pancreatic hormones. KGF is a potent in vivo mitogen for pancreatic ductal epithelial cells.


Subject(s)
Fibroblast Growth Factors , Growth Substances/administration & dosage , Pancreatic Ducts/cytology , Animals , Bromodeoxyuridine/administration & dosage , Bromodeoxyuridine/metabolism , Cell Division/drug effects , Epithelial Cells , Epithelium/drug effects , Epithelium/metabolism , Female , Fibroblast Growth Factor 10 , Fibroblast Growth Factor 7 , Injections, Intraperitoneal , Injections, Intravenous , Injections, Subcutaneous , Male , Nuclear Proteins/metabolism , Pancreatic Ducts/drug effects , Pancreatic Ducts/metabolism , Proliferating Cell Nuclear Antigen , Rats , Rats, Inbred Lew , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...